← Back to Search

Tetracycline Antibiotic

Doxycycline for Acneiform Eruptions

Phase 4
Waitlist Available
Research Sponsored by Lady Davis Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is comparing tetracyclines to isotretinoin for treatment of moderate to severe acneiform eruptions in cancer patients on tyrosine kinase inhibitors.

Eligible Conditions
  • Acneiform Eruptions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quantitative improvement in acneiform eruptions in cancer patients on tyrosine kinase inhibitors as defined by a change in Leeds Revised Acne Grading Scale.
Secondary outcome measures
Adverse events from the study medications as defined using the CTCAE version 5.0 guidelines
Quantitative change on patient's quality of life with treatment of the acneiform eruption as measured by the dermatology life quality index scale.
Response of malignancy to cancer therapy using RECIST v1.1 guidelines

Trial Design

2Treatment groups
Active Control
Group I: DoxycyclineActive Control1 Intervention
Doxycycline 100mg po once daily x 6 months
Group II: IsotretinoinActive Control1 Intervention
Isotretinoin 40mg po once daily x 6 months

Find a Location

Who is running the clinical trial?

Lady Davis InstituteLead Sponsor
43 Previous Clinical Trials
4,934 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Current OncologyJournal
Supportive Care Treatments for Toxicities of Anti-egfr and Other Targeted Agents
Melosky, B.. 2012. “Supportive Care Treatments for Toxicities of Anti-egfr and Other Targeted Agents”. Current Oncology. MDPI AG. doi:10.3747/co.19.1054.
Current OncologyJournal
Managing Treatment-related Adverse Events Associated with Egfr Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
Hirsh, V.. 2011. “Managing Treatment-related Adverse Events Associated with Egfr Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer”. Current Oncology. MDPI AG. doi:10.3747/co.v18i3.877.
Journal of the American Academy of DermatologyJournal
Acneiform Eruptions Associated with Epidermal Growth Factor Receptor–targeted Chemotherapy
DeWitt, Christine A., Alan E. Siroy, and Stephen P. Stone. 2007. “Acneiform Eruptions Associated with Epidermal Growth Factor Receptor–targeted Chemotherapy”. Journal of the American Academy of Dermatology. Elsevier BV. doi:10.1016/j.jaad.2006.06.046.
Supportive Care in CancerJournal
Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-associated Dermatologic Toxicities
Lacouture, Mario E., Milan J. Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B. Epstein, Beth Eaby-Sandy, Barbara A. Murphy, and MASCC Skin Toxicity Study Group. 2011. “Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-associated Dermatologic Toxicities”. Supportive Care in Cancer. Springer Science and Business Media LLC. doi:10.1007/s00520-011-1197-6.
All > Acne > Accutane
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top